GlassScriptPhysician profile
Olga B Kovacevic
NPI 1487630323
$8,458.92
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,263 · 2020: $1,455 · 2021: $1,783 · 2022: $1,808 · 2023: $1,953 · 2024: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,150.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,258.54 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $1,100.07 | 2019-2023 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $883.81 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $775.69 | 2019-2024 | |
| Lilly USA, LLC | $500.76 | 2020-2023 | Mounjaro, Jardiance, Emgality |
| Merck Sharp & Dohme LLC | $375.77 | 2019-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Astellas Pharma US INC | $330.65 | 2019-2022 | |
| Amarin Pharma, INC. | $308.72 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $304.71 | 2019-2024 | Jardiance |
| Xeris Pharmaceuticals, INC. | $273.69 | 2022-2024 | Keveyis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $267.32 | 2019-2023 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $245.22 | 2022 | |
| Glaxosmithkline, LLC. | $168.96 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $165.32 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $135.22 | 2019-2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olga Kovacevic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.